Monitor for any conversion of Series C Preferred into common shares and for potential future amendments that could signal a change in intent from passive to active. The presence of multiple healthcare-focused funds (Perceptive Advisors, Ikarian Capital, Cormorant Asset Management) filing 13Gs within the past 60 days suggests concentrated institutional interest, but no activist pressure is indicated.
Price Chart
Executive Summary
Foresite Capital Fund VI LP and affiliated entities disclosed a 6.0% beneficial ownership stake in IRulya Therapeutics Inc. via a Schedule 13G, indicating passive intent. The stake, held as Series C Preferred Stock on an as-converted basis, totals 652,039 common-equivalent shares. This is a new passive disclosure by a healthcare-focused investment firm, notable for the size of the position but neutral in directional impact given the passive filing type.
Key Financial Metrics
Key Facts
- Foresite Capital Fund VI LP and affiliates filed a Schedule 13G disclosing beneficial ownership of 652,039 shares of IRulya Therapeutics Inc. common stock, representing 6.0% of shares outstanding.
- The stake is held as Series C Preferred Stock on an as-converted basis, with 489,029 shares owned by Foresite Capital Fund VI LP and 163,010 shares by Foresite Public & Crossover Opportunities Fund I, L.P.
- James B. Tananbaum, managing member of the general partners, is deemed to have sole voting and dispositive power over all 652,039 shares.
- The filing certifies passive intent under Rule 13d-1(c), with no purpose of changing or influencing control of the issuer.
- The percentage is based on 10,841,470 common shares outstanding as of October 9, 2026, per the issuer's press release.
Financial Impact
6.0% beneficial ownership stake valued at an undisclosed amount; no transaction price provided.
Risk Factors
- Passive filing — no indication of activist intent; the stake may be held for investment only.
- Shares are held as convertible preferred; conversion could increase common share count and dilute existing holders.
- No financial terms or market price disclosed for the stake acquisition.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001104659-26-115859 |
| Document: 0001104659-26-115859-index.html | 0001104659-26-115859 |
| Document: 0001104659-26-115859.txt | 0001104659-26-115859 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $32.83 | awaiting T+20 | — | $32.16 (−2.03%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $32.16 (−20.13%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $32.16 (−20.13%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $32.16 (−20.13%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $32.16 (−20.13%) |
Oct 19, 2026 7d ago | 3 | $40.27 | awaiting T+20 | — | $32.16 (−20.13%) |
Oct 19, 2026 8d ago | 8-K | $34.45 | awaiting T+20 | — | $32.16 (−6.64%) |
Oct 14, 2026 12d ago | SC 13G | $33.23 | awaiting T+20 | — | $32.16 (−3.21%) |
Oct 14, 2026 12d ago | SC 13G | $33.23 | awaiting T+20 | — | $32.16 (−3.21%) |
Oct 6, 2026 20d ago | 8-K | $26.72 | awaiting T+20 | — | $32.16 (+20.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers